PhinC Development

Votre Partenaire en Pharmacologie Quantitative et Modélisation

Adoptez la meilleure stratégie de Modélisation & Simulation pour orienter les étapes clés de votre développement et optimiser ses coûts.

Découvrez Biotech.Boost !

Biotech.Boost est une offre de solutions sur mesure
pour propulser votre biotech lors des essais de la Phase 1
avec efficacité et efficience.

Nous comprenons les défis uniques auxquels sont confrontées
les startups biotechnologiques et offrons des solutions
sur mesure pour y répondre.

PhinC oriente les étapes clés de votre développement
et optimise ses coûts.

Modélisation intégrée au développement du médicament

Stratégie optimisée, du candidat médicament à la preuve de concept chez le patient.

Modèle pharmacocinétique physiologique

Développement optimisé dès la pré-clinique jusqu’aux essais de phase I/II

La pharmacocinétique de population

pour quantifier et d’identifier la source de variabilité d’une population

Pharmacocinétique NCA

L’étude complète de la Pharmacocinétique (PK) de votre candidat médicament

Analyse QT / QTc

Pionnier dans l’évaluation de la sécurité cardiaque en phase précoce

Solutions intégrées pour la phase 1

Offre conçue pour propulser les essais de la phase 1 des biotechs

Vous avez un projet ?

Les actualités de PhinC Development

[Webinaire] Translational Mechanistic Modeling : Applications for ADCs

PhinC Development is pleased to host an exclusive webinar dedicated to Translational Mechanistic Modeling: Applications for Antibody Drug Conjugates (ADCs). Discover how Model-Informed Drug Development (MIDD) strategies can accelerate and de-risk ADC programs.

New article: Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation

A first-in-class PBPK model for CLDN18.2-targeted ADCs using PK-Sim® and MoBi®. Read and discover the full article!

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

The FDA is taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.

Restez informé des dernières actualités

Ils nous font confiance

"Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity."

"Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs."

"The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program."

Analyses des interactions médicamenteuses (DDI)